|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein-associated phospholipase A2 (Lp-PLA2) mediates vascular inflammation through the regulation of lipid metabolism in blood, thus, it has been extensively investigated to identify its role in vascular inflammation-related diseases, mainly atherosclerosis.
|
31140638 |
2020 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Compared with the normal group, the levels of total cholesterol, triglyceride and LDL-C were increased, HDL-C levels were decreased, and atherosclerosis index was increased in the PLA2G7 shRNA group, NC group and blank group (all P < 0.05).
|
31053299 |
2019 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to determine the association between lipoprotein-associated phospholipase A2 (Lp-PLA2), a marker for inflammation in the vessel wall and independently associated with atherosclerosis, and the incidence of diabetic kidney disease (DKD) in patients with type 2 diabetes (T2D).
|
30904742 |
2019 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These patients had a higher iEAT, and their HDL contained less cholesterol and more apoA-II and lipoprotein-associated phospholipase A2 than patients without subclinical atherosclerosis.
|
30526614 |
2018 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, long-term inhibition of endogenous Lp-PLA2 activity with darapladib was not associated with a change in plaque progression and vulnerability indices after 6 months of therapy, and the endogenous Lp-PLA2 pathway may not play a direct role in the progression of early atherosclerosis in humans.
|
29135482 |
2018 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Since rs10846744 has been reported in association with Lp-PLA2 mass and activity, we hypothesized that inflammatory pathways might mediate the association of rs10846744 with atherosclerosis.
|
30289950 |
2018 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined RNAi of Lp-PLA2 and YKL-40 is superior to RNAi of Lp-PLA2 or YKL-40 alone in ameliorating atherosclerosis.
|
30138439 |
2018 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
High-sensitivity C-reactive protein (hs-CRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2) have been reported to be independent predictors of atherosclerosis.
|
30094934 |
2018 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lp-PLA2 mass is positively correlated with subclinical atherosclerosis determined by ACAS, ICAS and ECAS in North Chinese, particularly in male and older participants, suggesting that serum Lp-PLA2 mass might be potential biomarker for the detection of ACAS in the adults.
|
29424477 |
2018 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Besides, the relationship between miR-3188 and RhoA/ROCK pathway was explored. miR-3188 was downregulated in AS patients, while the levels of Lp-PLA2 in AS patients were increased.
|
29442044 |
2017 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a promising therapeutic target for atherosclerosis, Alzheimer's disease, and diabetic macular edema.
|
29193967 |
2017 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the expression of Lp-PLA2 on leucocytes and different monocyte subpopulations and their possible role in uremia, inflammation, and atherosclerosis.
|
27992874 |
2017 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a potentially important pathogenic factor participating in the progression of atherosclerosis.
|
29201198 |
2017 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Objective To evaluate the association between plasma lipoprotein-associated phospholipase A2 (Lp-PLA2; known to release inflammatory mediators that promote atherosclerosis) and coronary heart disease (CHD) in Chinese patients.
|
28222638 |
2017 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the present study provides initial evidence that Lp-PLA2 is able to cause endothelial dysfunction in an <i>in vitro</i> model of atherosclerosis, and the effects of Lp-PLA2 on endothelial dysfunction was at least partially a result of the downregulation of AMPKα, thus contributing to the progression of atherosclerosis.
|
28413519 |
2017 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein-associated phospholipase A2 (Lp-PLA<sub>2</sub>) levels are associated with the development of atherosclerosis.
|
27905470 |
2016 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to investigate whether Lp-PLA2 is related to subclinical atherosclerosis, independently from traditional risk factors, in a general Japanese population by analyses of both the observational study and Mendelian randomization using V279F polymorphism.
|
26775119 |
2016 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We examined the association of LpPLA2 activity and ApoC3 LOF mutations and incident cardiovascular disease (CVD) (defined as coronary heart disease [CHD] plus ischemic stroke) and all-cause mortality in the biracial longitudinal Atherosclerosis Risk In Communities (ARIC) study.
|
26117401 |
2015 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is being evaluated as a therapeutic target for treatment of atherosclerosis.
|
23439604 |
2013 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, disagreement continues to exist regarding the validity of Lp-PLA(2) as an independent marker of atherosclerosis and a scientifically justified target for intervention.
|
22665167 |
2012 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently completed experimental animal studies, human biomarker data, vascular imaging studies, and genome-wide atherosclerosis studies provide the rationale for proceeding with clinical outcome trials directed at inhibition of secretory phospholipase A(2) and lipoprotein-associated phospholipase A(2).
|
22802388 |
2012 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of the lipoprotein-associated phospholipase A(2) gene (PLA2G7) in atherosclerosis remains controversial.
|
21834908 |
2011 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an enzyme which binds to oxidized LDL and has a pro-inflammatory role in the pathogenesis of atherosclerosis.
|
21870060 |
2011 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we evaluated the effects of a specific lp-PLA2 inhibitor on atherosclerosis in ApoE-deficient mice and its associated mechanisms.
|
21909350 |
2011 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results uncover a new link between oxLDL and lp-PLA2, and may provide insight into this interaction in the context of atherosclerosis.
|
19910444 |
2010 |